articleThe LancetFeb 3, 2023Closed access

Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials

ABAlexa B. KimballGBGregor B. E. JemecAAAfsáneh AlaviZRZ. ReguiaïABAlice B. Gottlieb

Zealand University Hospital · Mayo Clinic in Arizona · +13 more institutions

PubMed
Indexed incrossrefpubmed

Abstract

No abstract available for this paper.

Citation impact

295
total citations
FWCI
79.18
Percentile
100%
References
37
Citations per year

Authors

32

Topics & keywords

Topics
Keywords
  • Hidradenitis suppurativa
  • Medicine
  • Placebo
  • Secukinumab
  • Clinical endpoint
  • Clinical trial
  • Surgery
  • Randomized controlled trial
No related works found for this paper.